Synthesis and cytotoxic activity of certain benzothiazole derivatives against human MCF-7 cancer cell line
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Mohamed L.W. | |
dc.contributor.author | Taher A.T. | |
dc.contributor.author | Rady G.S. | |
dc.contributor.author | Ali M.M. | |
dc.contributor.author | Mahmoud A.E. | |
dc.contributor.other | Pharmaceutical Organic Chemistry Department | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | Cairo University | |
dc.contributor.other | Cairo | |
dc.contributor.other | Egypt; Pharmaceutical Organic Chemistry Department | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | October University for Modern Sciences and Arts (MSA) University | |
dc.contributor.other | Cairo | |
dc.contributor.other | Egypt; Directorate of Health Affairs | |
dc.contributor.other | Ministry of Health | |
dc.contributor.other | Giza | |
dc.contributor.other | Egypt; Biochemistry Department | |
dc.contributor.other | Division of Genetic Engineering and Biotechnology | |
dc.contributor.other | National Research Centre | |
dc.contributor.other | Giza | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:21Z | |
dc.date.available | 2020-01-09T20:41:21Z | |
dc.date.issued | 2017 | |
dc.description | Scopus | |
dc.description.abstract | A new series of benzothiazole has been synthesized as cytotoxic agents. The new derivatives were tested for their cytotoxic activity toward the human breast cancer MCF-7 cell line against cisplatin as the reference drug. Many derivatives revealed good cytotoxic effect, whereas four of them, 4, 5c, 5d, and 6b, were more potent than cisplatin, with IC50 values being 8.64, 7.39, 7.56, and 5.15�?m compared to 13.33�?m of cisplatin. The four derivatives� cytotoxic activity was accompanied by regulating free radicals production, by increasing the activity of superoxide dismutase and depletion of intracellular reduced glutathione, catalase, and glutathione peroxidase activities, accordingly, the high production of hydrogen peroxide, nitric oxide, and other free radicals causing tumor cell death as monitored by reduction in the synthesis of protein and nucleic acids. Most of the tested compounds showed potent to moderate growth inhibitory activity; in particular, compound 6b exhibited the highest activity suggesting it is a lead compound in cytotoxic activity. � 2016 John Wiley & Sons A/S. | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=4000150314&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.1111/cbdd.12879 | |
dc.identifier.doi | PubMed ID 27700014 | |
dc.identifier.issn | 17470277 | |
dc.identifier.other | https://doi.org/10.1111/cbdd.12879 | |
dc.identifier.other | PubMed ID 27700014 | |
dc.identifier.uri | https://t.ly/xRmJm | |
dc.language.iso | English | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.relation.ispartofseries | Chemical Biology and Drug Design | |
dc.relation.ispartofseries | 89 | |
dc.subject | October University for Modern Sciences and Arts | |
dc.subject | جامعة أكتوبر للعلوم الحديثة والآداب | |
dc.subject | University of Modern Sciences and Arts | |
dc.subject | MSA University | |
dc.subject | anticancer | en_US |
dc.subject | antioxidant | en_US |
dc.subject | benzothiazole | en_US |
dc.subject | cytotoxic | en_US |
dc.subject | MCF-7 | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [3 phenyl 3,3a dihydro thiazolo[4,5-b](1,4)benzothiazin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [3 phenyl(1,3)thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [3 phenylthiazolo[4,5-b]quinoxalin 2(3h) ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4 (2 hydroxybenzylidene) 5 oxo 3 phenyl thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4 (3 hydroxybenzylidene) 5 oxo 3 phenyl thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4 (4 chlorobenzylidene) 5 oxo 3 phenyl thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4 (4 hyrdoxybenzylidene) 5 oxo 3 phenyl thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4 methyl 5 oxo 3 phenyl(1,3)thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [4,5 dioxo 3 phenyl(1,3)thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [5 oxo 3 phenyl(1,3)thiazolidin 2 ylidene]acetonitrile | en_US |
dc.subject | 2 (1,3 benzothiazol 2 yl) 2 [[4 (furan 2 yl)methyl] 5 oxo 3 phenyl thiazolidin 2 yli dene]acetonitrile | en_US |
dc.subject | 4 [2 (1,2 dihydro 1,5 dimethyl 2 phenylpyrazol 3 one 4 yl)diazen 1 yl] 5 ox 3 phenylthiazolidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 (3 hydroxyphenyl)diazen 1 yl]5 oxo 3 phenylthiaazolidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 (3 methylphenyl)diazen 1 yl]5 oxo 3 phenylthiazolidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 (4 chlorophenyl)diazen 1 yl]5 oxo 3 phenylthiaazolidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 (4 hydroxyphenyl)diazen 1 yl]5 oxo 3 phenylthiaazolidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 [1 phenyl 1h pyrazol 5(4h) one 3 yl]diazen 1 yl] 5 oxo 3 phenylthiazo lidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | 4 [2 [1h pyrazol 5(4h) one 3 yl]diazen 1 yl] 5 oxo 3 phenylthiazo lidin 2 ylidene 2 1,3 benzothiazol 2 yl acenotrile | en_US |
dc.subject | benzothiazole derivative | en_US |
dc.subject | catalase | en_US |
dc.subject | cisplatin | en_US |
dc.subject | cytotoxic agent | en_US |
dc.subject | glutathione | en_US |
dc.subject | glutathione peroxidase | en_US |
dc.subject | hydrogen peroxide | en_US |
dc.subject | nitric oxide | en_US |
dc.subject | superoxide dismutase | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | antioxidant | en_US |
dc.subject | benzothiazole derivative | en_US |
dc.subject | antineoplastic activity | en_US |
dc.subject | antioxidant activity | en_US |
dc.subject | Article | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug effect | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | enzyme activity | en_US |
dc.subject | IC50 | en_US |
dc.subject | MCF-7 cell line | en_US |
dc.subject | priority journal | en_US |
dc.subject | carbon nuclear magnetic resonance | en_US |
dc.subject | drug screening | en_US |
dc.subject | human | en_US |
dc.subject | mass spectrometry | en_US |
dc.subject | proton nuclear magnetic resonance | en_US |
dc.subject | Antioxidants | en_US |
dc.subject | Benzothiazoles | en_US |
dc.subject | Carbon-13 Magnetic Resonance Spectroscopy | en_US |
dc.subject | Drug Screening Assays, Antitumor | en_US |
dc.subject | Humans | en_US |
dc.subject | Inhibitory Concentration 50 | en_US |
dc.subject | Mass Spectrometry | en_US |
dc.subject | MCF-7 Cells | en_US |
dc.subject | Proton Magnetic Resonance Spectroscopy | en_US |
dc.title | Synthesis and cytotoxic activity of certain benzothiazole derivatives against human MCF-7 cancer cell line | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Taher, A.T., Georgey, H.H., El-Subbagh, H.I., (2012) Eur. J. Med. Chem., 47, p. 445; Bashandy, M.S., ElSaid, M.S., Arafa, R.K., Ghorab, M.M., (2014) J. Enzyme Inhib. Med. Chem., 29, p. 619; Taher, A.T., Mohammed, L.W., (2013) Arch. Pharm. Res., 36, p. 684; Ghorab, M.M., Alsaid, M.S., Higgins, M., Dinkova-Kostova, A.T., Shahat, A.A., Elghazawy, N.H., Arafa, R.K., (2016) J. Enzyme Inhib. Med. Chem., 31, p. 7; Taher, A.T., Hegazy, G.H., (2013) Arch. Pharm. Res., 36, p. 573; http://www.cancer.gov/about-cancer/treatment/drugs/breast; Geronikaki, A., Babaev, E., Dearden, J., Dehaen, W., Filimonov, D., Galaeva, I., Krajneva, V., Voronina, T., (2004) Bioorg. Med. Chem., 12, p. 6559; Vacondio, F., Mor, M., Silva, C., Zuliani, V., Rivara, M., Rivara, S., Bordi, F., Testa, B., (2004) Eur. J. Pharm. Sci., 23, p. 89; Cheng, G., Wang, L.-L., Qu, W.-S., Long, L., Cui, H., Liu, H.-Y., Cao, Y.-L., Li, S., (2005) Acta Pharmacol. Sin., 26, p. 1460; Moreno-D�az, H., Villalobos-Molina, R., Ortiz-Andrade, R., D�az-Couti�o, D., Medina-Franco, J.L., Webster, S.P., Binnie, M., Navarrete-V�zquez, G., (2008) Bioorg. Med. Chem. Lett., 18, p. 2871; Amnerkar, N.D., Bhusari, K.P., (2010) Eur. J. Med. Chem., 45, p. 149; Karal?, N., G�zel, �., �zsoy, N., �zbey, S., Salman, A., (2010) Eur. J. Med. Chem., 45, p. 1068; Choi, S.-J., Park, H.J., Lee, S.K., Kim, S.W., Han, G., Choo, H.-Y.P., (2006) Bioorg. Med. Chem., 14, p. 1229; Lavergne, O., Fernandes, A.-C., Br�hu, L., Sidhu, A., Br�zak, M.-C., Pr�vost, G., Ducommun, B., Contour-Galcera, M.-O., (2006) Bioorg. Med. Chem. Lett., 16, p. 171; Tasler, S., M�ller, O., Wieber, T., Herz, T., Pegoraro, S., Saeb, W., Lang, M., Sch�chtele, C., (2009) Bioorg. Med. Chem., 17, p. 6728; Bhuva, H.A., Kini, S.G., (2010) J. Mol. Graph. Model., 29, p. 32; Mohamed, M.F., Mohamed, M.S., Shouman, S.A., Fathi, M.M., Abdelhamid, I.A., (2012) Appl. Biochem. Biotechnol., 168, p. 1153; Ibrahim, N.M., Yosef, H.A.A., Ewies, E.F., Mahran, M.R.H., Ali, M.M., Mahmoud, A.E., (2015) J. Braz. Chem. Soc., 26, p. 1086; Prabhu, P.P., Panneerselvam, T., Shastry, C.S., Sivakumar, A., Pande, S.S., (2015) J. Saudi Chem. Soc., 19, p. 181; Elzahabi, H.S.A., (2011) Eur. J. Med. Chem., 46, p. 4025; Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Boyd, M.R., (1990) J. Natl Cancer Inst., 82, p. 1107; Paglia, D.E., Valentine, W.N., (1967) J. Lab. Clin. Med., 70, p. 158; Aebi, H., (1984) Method of Enzymatic Analysis, pp. 673-679. , Academic Press, New York; Marklund, S., Marklund, G., (1974) Eur. J. Biochem., 47, p. 469; Wolff, S.P., (1994) Methods Enzymol., 233, p. 182; Montgomery, H.A.C., Dymock, J.F., (1961) Analyst, 86, p. 414; Ellman, G.L., (1959) Arch. Biochem. Biophys., 82, p. 70; Zhou, T., Zhou, G., Song, W., Eguchi, N., Lu, W., Lundin, E., Jin, T., Nordberg, G., (1999) Toxicology, 142, p. 1; Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., (1951) J. Biol. Chem., 103, p. 265; Refaat, H.M., (2010) Eur. J. Med. Chem., 45, p. 2949; Akar, D., ?ncesu, Z., G�ndo?du-Karaburun, N., Benkli, K., Ifl?kda?, ?., (2004) Turk. J. Pharm. Sci., 1, p. 193; Sindhu, T.J., Chandran, M., Paul, D., Bhat, A.R., Krishnakumar, K., (2014) Int. J. Pharm. Res. Sch., 3, p. 24; Ismail, M.M., Mohamed, E.A., Abass, M., (1997) Chem. Pap., 51, p. 43; Shabaan, M., Taher, A.T., Osman, E.O., (2011) Eur. J. Chem., 2, p. 365 | |
dcterms.source | Scopus |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- avatar_scholar_256.png
- Size:
- 6.31 KB
- Format:
- Portable Network Graphics
- Description: